As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Prevention:1. DNA vaccine 2. RNA vaccine 3. protein vaccine 4. viral vector vaccine
Treatment: 1. Antibody therapy 2. Cell therapy 3. Nanotherapy 4. siRNA therapy
Antibody therapy is a common practice in the prevention and treatment of infectious diseases. Antibodies play a crucial role in the immune system. They can directly bind to the virus and neutralize it. Once marked by antibodies, the virus in the body follows a process that leads to its elimination. Specific antibodies against COVID-19 are obtained by extracting blood from recovered individuals.
Due to the lengthy preparation time for antibodies, numerous companies and research institutions around the world are accelerating antibody development to prepare for potential future outbreaks of COVID-19.
marketing@medicilon.com
ABOUT
